Many of the drugs tested in Alzheimer’s disease so far, and some still in development, aim to block or break up proteins associated with the progression of the memory-robbing disorder. Athira Pharma is taking a different approach—neuron regeneration. And it’s doing so by a tapping a protein first discovered in the liver.

Seattle-based Athira has encouraging results from early clinical trials, and it’s now looking ahead to larger tests in Alzheimer’s as well as Parkinson’s disease. With those studies expected to start in the coming year, Athira is turning to the public markets to fund its clinical development plans. In paperwork Read more »